Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma

Tasnuva D. Kabir, Clarissa Ganda, Rikki M. Brown, Dianne J. Beveridge, Kirsty L. Richardson, Vishal Chaturvedi, Patrick Candy, Michael Epis, Larissa Wintle, Felicity Kalinowski, Christina Kopp, Lisa M. Stuart, George C. Yeoh, Jacob George, Peter J. Leedman – 18 August 2017 – Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR).

Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses

Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Al Asadi, Ronald Mora, Laura Kulik, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Frank H. Miller, Vahid Yaghmai, Daniel Ganger, Robert J. Lewandowski, Riad Salem – 18 August 2017 – Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization.

Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses

Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Al Asadi, Ronald Mora, Laura Kulik, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Frank H. Miller, Vahid Yaghmai, Daniel Ganger, Robert J. Lewandowski, Riad Salem – 18 August 2017 – Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization.

MicroRNA‐337‐3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation

Céline Demarez, Claude Gérard, Sabine Cordi, Alexis Poncy, Younes Achouri, Nicolas Dauguet, David A. Rosa, Patrick T. Gunning, Isabelle Manfroid, Frédéric P. Lemaigre – 17 August 2017 – Transcriptional networks control the differentiation of the hepatocyte and cholangiocyte lineages from embryonic liver progenitor cells and their subsequent maturation to the adult phenotype. However, how relative levels of hepatocyte and cholangiocyte gene expression are determined during differentiation remains poorly understood. Here, we identify microRNA (miR)‐337‐3p as a regulator of liver development.

Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States

Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri – 17 August 2017 – Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver transplantation (LT) in the United States. We aimed to determine the temporal trend behind the rise in obesity and NASH‐related additions to the LT waitlist in the United States and make projections for future NASH burden on the LT waitlist.

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, Manal F. Abdelmalek, Guruprasad P. Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V. Kowdley, Antonio Craxi, Krzysztof Simon, Laurent Fischer, Liza Melchor‐Khan, Jeffrey Vest, Brian L.

Increased myocardial contractility identifies patients with decompensated cirrhosis requiring liver transplantation

Christian Jansen, Alexander Cox, Robert Schueler, Matthias Schneider, Jennifer Lehmann, Michael Praktiknjo, Alessandra Pohlmann, Johannes Chang, Steffen Manekeller, Georg Nickenig, Gabriela Berlakovich, Christian P. Strassburg, Christoph Hammerstingl, Katharina Staufer, Jonel Trebicka – 17 August 2017 – Late allocation of organs for transplant impairs post–liver transplantation (LT) survival. Cardiac dysfunction, especially diastolic and autonomic dysfunction, is frequent and plays an important role in the prognosis of patients with cirrhosis.

Subscribe to